Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis

References

• van Beurden-TanCHYFrankenMGBlommesteinHMUyl-de GrootCASonneveldPSystematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myelomaJ Clin Oncol201735121312131928240968
   PubMed Web of Science ®Google Scholar
• BottaDCCCilibertoDRossiMNetwork meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patientsBlood Adv20171745546629296961
   PubMed Web of Science ®Google Scholar
• SalantiGAdesAEIoannidisJPGraphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJ Clin Epidemiol201164216317120688472
   PubMed Web of Science ®Google Scholar
• San MiguelJWeiselKMoreauPPomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialLancet Oncol201314111055106624007748
   PubMed Web of Science ®Google Scholar
• RichardsonPGSiegelDSVijRPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood2014123121826183224421329
   PubMed Web of Science ®Google Scholar
• MorganGPalumboADhanasiriSOverall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneBr J Haematol2015168682082325403264
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSSOverall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialLancet Haematol2016311e506e51527751707
   PubMed Web of Science ®Google Scholar
• DimopoulosMALonialSWhiteDElotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthBr J Haematol2017178689690528677826
   PubMed Web of Science ®Google Scholar
• HajekRMassziTPetrucciMTA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)Leukemia201731110711427416912
   PubMed Web of Science ®Google Scholar
• HouJJinJXuYRandomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation studyJ Hematol Oncol201710113728683766
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood2007110103557356017690257
   PubMed Web of Science ®Google Scholar
• DimopoulosMSpencerAAttalMLenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med2007357212123213218032762
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionJ Clin Oncol200725253892390117679727
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med2007357212133214218032763
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAANiesvizkyRHohlRJPhase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myelomaLeuk Lymphoma200950455956519373653
   PubMed Web of Science ®Google Scholar
• DimopoulosMAChenCSpencerALong-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia200923112147215219626046
   PubMed Web of Science ®Google Scholar
• GarderetLIacobelliSMoreauPSuperiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationJ Clin Oncol201230202475248222585692
   PubMed Web of Science ®Google Scholar
• HjorthMHjertnerOKnudsenLMThalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyEur J Haematol201288648549622404182
   PubMed Web of Science ®Google Scholar
• KropffMBaylonHGHillengassJThalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trialHaematologica201297578479122133776
   PubMed Web of Science ®Google Scholar
• DimopoulosMSiegelDSLonialSVorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyLancet Oncol201314111129114024055414
   PubMed Web of Science ®Google Scholar
• WhiteDKassimABhaskarBYiJWamstadKPatonVEResults from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myelomaCancer2013119233934722811009
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSSPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol201415111195120625242045
   PubMed Web of Science ®Google Scholar
• LonialSDimopoulosMPalumboAElotuzumab therapy for relapsed or refractory multiple myelomaN Engl J Med2015373762163126035255
   PubMed Web of Science ®Google Scholar
• OrlowskiRZGerchevaLWilliamsCA phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaAm J Heamtol20159014249
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMACarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
   PubMed Web of Science ®Google Scholar
• DimopoulosMAOriolANahiHDaratumumab, lenalidomide, and dexamethasone for multiple myelomaN Engl J Med2016375141319133127705267
   PubMed Web of Science ®Google Scholar
• DimopoulosMAMoreauPPalumboACarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyLancet Oncol2016171273826671818
   PubMed Web of Science ®Google Scholar
• JakubowiakAOffidaniMPegourieBRandomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMBlood2016127232833284027091875
   PubMed Web of Science ®Google Scholar
• MoreauPMassziTGrzaskoNOral ixazomib, lenalidomide, and dexamethasone for multiple myelomaN Engl J Med2016374171621163427119237
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPFinal overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myelomaCancer2016122132050205627191689
   PubMed Web of Science ®Google Scholar
• PalumboAChanan-KhanAWeiselKDaratumumab, bortezomib, and dexamethasone for multiple myelomaN Engl J Med2016375875476627557302
   PubMed Web of Science ®Google Scholar